Castle Biosciences Inc

1. 1

   Election of Three Class I Directors

   ManagementBoard: FOR

   Election of three Class I director nominees—Ellen Goldberg, Miles D. Harrison, and Tiffany P. Olson—to hold office until the 2029 annual meeting of stockholders.

2. 2

   Ratification of Selection of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the Audit Committee’s selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Advisory Approval of Executive Compensation (Say-on-Pay

   ManagementBoard: FOR

   Non-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the Proxy Statement (Say-on-Pay).

   More detail

   This is a non-binding, advisory vote asking stockholders to approve the Company’s executive compensation as disclosed in the proxy, including the Compensation Discussion and Analysis and the compensation tables. Management is seeking shareholder approval to confirm that the mix of compensation elements—base salary, an annual performance-based cash bonus tied primarily to corporate revenue and strategic milestones, and long-term equity awards (a mix of time-based RSUs and performance-based PSUs tied to multi-year revenue and adjusted EBITDA targets)—is appropriately aligned with stockholder interests. The Company emphasizes a pay-for-performance design: a significant portion of CEO and NEO pay is “at risk” (including PSUs representing 50% of the CEO’s target equity in 2025) and annual cash bonuses are funded based on attainment of objective corporate goals. The Board highlights governance safeguards used to set pay, such as engagement with an independent compensation consultant (AON), active stockholder outreach, an independent Compensation Committee, stock ownership guidelines, a clawback policy, and prohibitions on hedging and pledging. The proxy also discloses that specific PSU targets are withheld from public disclosure due to competitive sensitivity, which may be a point of investor scrutiny despite management’s rationale. Although the vote is advisory and non-binding, the Board commits to consider the outcome in future compensation decisions; prior stockholder support has been strong (about 94% in 2025). The Board recommends a vote FOR, arguing that the program supports retention, aligns management incentives with long-term value creation, and reflects market benchmarking and stockholder feedback.

4. 4

   Approval of the Company’s Non-Employee Director Compensation Policy

   ManagementBoard: FOR

   Approve the newly adopted non-employee director compensation policy, which sets cash retainers and equity grant values (initial and annual) for non-employee directors and will supersede prior policies.

   More detail

   This proposal requests stockholder approval of a formal Director Compensation Policy that governs cash retainers and equity awards for non-employee directors and will supersede prior arrangements. Management is seeking approval to adopt market-competitive updates recommended by its independent consultant (AON) following benchmarking, including increases to the annual board service retainer and adjustments to the initial equity grant (to $400,000) and the annual equity grant (to $260,000), along with defined vesting and proration mechanics and a six-month eligibility rule for annual grants. The Board argues approval will help attract and retain qualified independent directors and provides transparent, pre-approved automatic grant mechanics for initial and annual awards, while maintaining limits on total annual director compensation and requiring annual review by the Compensation Committee. The policy includes standard governance protections—committee oversight, disclosure requirements, reimbursement of reasonable expenses, and change-in-control vesting provisions—and ties administration to the 2019 Equity Incentive Plan. Potential investor questions include increased director pay, dilution from larger equity grants, and whether the market benchmarking fully accounts for company size and growth stage; management’s response is that the changes are modest, recommended by an independent adviser, and intended to preserve board quality. The Board recommends FOR, saying the policy balances competitiveness, governance safeguards, and disclosure and will be in the best interest of the Company and its stockholders.

Upcoming shareholder meetings at Castle Biosciences Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Castle Biosciences Inc 2026 annual meeting?

Castle Biosciences Inc (CSTL) holds its 2026 annual shareholder meeting on Thursday, May 28, 2026.

What is the record date for the Castle Biosciences Inc 2026 meeting?

The record date for the Castle Biosciences Inc 2026 meeting is Wednesday, April 1, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Castle Biosciences Inc's 2026 meeting?

The board is presenting 3 director nominees at the Castle Biosciences Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Castle Biosciences Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Castle Biosciences Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.